These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24638211)

  • 41. Relation of haemofilter type to venous catheter resistance is crucial for filtration performance and haemocompatibility in CVVH--an in vitro study.
    Unger JK; Haltern C; Portz B; Dohmen B; Gressner A; Rossaint R
    Nephrol Dial Transplant; 2006 Aug; 21(8):2191-201. PubMed ID: 16567341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?
    Oudemans-van Straaten HM; Wester JPJ; de Pont ACJM; Schetz MRC
    Intensive Care Med; 2006 Feb; 32(2):188-202. PubMed ID: 16453140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Convective and adsorptive removal of beta2-microglobulin during predilutional and postdilutional hemofiltration.
    Padrini R; Canova C; Conz P; Mancini E; Rizzioli E; Santoro A
    Kidney Int; 2005 Nov; 68(5):2331-7. PubMed ID: 16221237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Blood flow reductions during continuous renal replacement therapy and circuit life.
    Baldwin I; Bellomo R; Koch B
    Intensive Care Med; 2004 Nov; 30(11):2074-9. PubMed ID: 15448889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Presentation of multivariate data for clinical use: The Framingham Study risk score functions.
    Sullivan LM; Massaro JM; D'Agostino RB
    Stat Med; 2004 May; 23(10):1631-60. PubMed ID: 15122742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EXCESS LACTATE: AN INDEX OF REVERSIBILITY OF SHOCK IN HUMAN PATIENTS.
    BRODER G; WEIL MH
    Science; 1964 Mar; 143(3613):1457-9. PubMed ID: 14107454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control.
    Uchino S; Fealy N; Baldwin I; Morimatsu H; Bellomo R
    Nephron Clin Pract; 2003; 94(4):c94-8. PubMed ID: 12972719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration.
    Uchino S; Fealy N; Baldwin I; Morimatsu H; Bellomo R
    Intensive Care Med; 2003 Apr; 29(4):575-8. PubMed ID: 12577144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous renal replacement therapy in critically ill patients.
    Ronco C; Bellomo R; Ricci Z
    Nephrol Dial Transplant; 2001; 16 Suppl 5():67-72. PubMed ID: 11509688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is the renal replacement method of first choice for intensive care patients?
    Vanholder R; Van Biesen W; Lameire N
    J Am Soc Nephrol; 2001 Feb; 12 Suppl 17():S40-3. PubMed ID: 11251030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transfusion requirements during continuous veno-venous haemofiltration: -the importance of filter life.
    Cutts MW; Thomas AN; Kishen R
    Intensive Care Med; 2000 Nov; 26(11):1694-7. PubMed ID: 11193279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Continuous renal replacement therapy in critically ill patients: monitoring circuit function.
    Holt AW; Bierer P; Bersten AD; Bury LK; Vedig AE
    Anaesth Intensive Care; 1996 Aug; 24(4):423-9. PubMed ID: 8862637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration.
    Langenecker SA; Felfernig M; Werba A; Mueller CM; Chiari A; Zimpfer M
    Crit Care Med; 1994 Nov; 22(11):1774-81. PubMed ID: 7956281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation.
    Webb AR; Mythen MG; Jacobson D; Mackie IJ
    Intensive Care Med; 1995 Jan; 21(1):84-93. PubMed ID: 7560483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bacterial/fungal growth in a combined parenteral nutrition solution.
    Mershon J; Nogami W; Williams JM; Yoder C; Eitzen HE; Lemons JA
    JPEN J Parenter Enteral Nutr; 1986; 10(5):498-502. PubMed ID: 3093707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microbial growth patterns in a total parenteral nutrition formulation containing lipid emulsion.
    Gilbert M; Gallagher SC; Eads M; Elmore MF
    JPEN J Parenter Enteral Nutr; 1986; 10(5):494-7. PubMed ID: 3093706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nationwide epidemic of septicemia caused by contaminated infusion products. IV. Growth of microbial pathogens in fluids for intravenous infusions.
    Maki DG; Martin WT
    J Infect Dis; 1975 Mar; 131(3):267-72. PubMed ID: 236343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microbiol growth in lipid emulsions used in parenteral nutrition.
    Melly MA; Meng HC; Schaffner W
    Arch Surg; 1975 Dec; 110(12):1479-81. PubMed ID: 982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Building and validation of a prognostic model for predicting extracorporeal circuit clotting in patients with continuous renal replacement therapy.
    Fu X; Liang X; Song L; Huang H; Wang J; Chen Y; Zhang L; Quan Z; Shi W
    Int Urol Nephrol; 2014 Apr; 46(4):801-7. PubMed ID: 24638211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-anticoagulation pediatric continuous renal replacement therapy methods to increase circuit life.
    Raina R; Sethi S; Khooblall A; Kher V; Deshpande S; Yerigeri K; Pandya A; Nair N; Datla N; McCulloch M; Bunchman T; Davenport A
    Hemodial Int; 2022 Apr; 26(2):147-159. PubMed ID: 34989465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.